Accepted Manuscript Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study)
James E. Sharman, Tony Stanton, Christopher M. Reid, Anthony Keech, Philip Roberts-Thomson, Simon Stewart, Robert Greenough, Michael Stowasser, Walter P. Abhayaratna PII: DOI: Reference:
S1551-7144(17)30183-0 doi: 10.1016/j.cct.2017.08.010 CONCLI 1619
To appear in:
Contemporary Clinical Trials
Received date: Revised date: Accepted date:
8 March 2017 11 August 2017 14 August 2017
Please cite this article as: James E. Sharman, Tony Stanton, Christopher M. Reid, Anthony Keech, Philip Roberts-Thomson, Simon Stewart, Robert Greenough, Michael Stowasser, Walter P. Abhayaratna , Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Concli(2017), doi: 10.1016/ j.cct.2017.08.010
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT 1
Targeted LOWering of Central Blood Pressure in patients with hypertension: baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study) James E. Sharmana, Tony Stantonb,c, Christopher M. Reidd,e, Anthony Keechf, Philip RobertsThomsona,g, Simon Stewarth , Robert Greenoughi, Michael Stowasserj, Walter P. Abhayaratnai. a
PT
Menzies Institute for Medical Research, University of Tasmania, Hobart, AUSTRALIA. Sunshine Coast University Hospital, Birtinya, AUSTRALIA. cSchool of Medicine, University of Queensland, Brisbane, AUSTRALIA. dCentre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, AUSTRALIA. eSchool of Public Health, Curtin University, Perth, AUSTRALIA. fSydney Medical School, NHMRC Clinical Trials Centre, University of Sydney, Sydney, AUSTRALIA. gRoyal Hobart Hospital, Department of Cardiology, Hobart, AUSTRALIA h Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, AUSTRALIA. iAustralia National University, Canberra Hospital, Canberra, Australian Capital Territory, AUSTRALIA. jEndocrine Hypertension Research Centre, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, AUSTRALIA.
MA
NU
SC
RI
b
EP T
ED
Funding: The study is supported by a National Health and Medical Research Council of Australia (NHMRC) Project Grant (reference 103787). CMR and SS are supported by NHMRC Research Fellowships 1045862 and 1041796 respectively. Completion of this paper was made possible for JES through funding from the High Blood Pressure Research Council of Australia Franco-Australian Exchange Program, the Menzies Institute for Medical Research and a Mobility Scholarship from L’Institut Servier.
AC C
Corresponding author: Professor James E. Sharman Menzies Institute for Medical Research, University of Tasmania Private Bag 23, Hobart, 7000, AUSTRALIA. Phone: +61 3 6226 4709 Fax: +61 3 6226 7704 Email: [email protected] Running title: Targeted central blood pressure therapy
ACCEPTED MANUSCRIPT 2
Abstract Background. High blood pressure (BP) is the most common modifiable cause of death from cardiovascular disease. Lowering BP with medication improves patient outcomes, but even in populations with normal upper arm (brachial) BP there remains considerable residual risk for
PT
cardiovascular disease and this may be due to persistently elevated central BP. There has never been a trial to determine the value of targeted central BP lowering among patients with
RI
hypertension, and this was the aim of this study.
SC
Methods. This is a multi-centre, randomized, open-label, blinded endpoint trial among 308 patients treated for uncomplicated hypertension with controlled brachial BP (
James E. Sharman, Tony Stanton, Christopher M. Reid, Anthony Keech, Philip Roberts-Thomson, Simon Stewart, Robert Greenough, Michael Stowasser, Walter P. Abhayaratna PII: DOI: Reference:
S1551-7144(17)30183-0 doi: 10.1016/j.cct.2017.08.010 CONCLI 1619
To appear in:
Contemporary Clinical Trials
Received date: Revised date: Accepted date:
8 March 2017 11 August 2017 14 August 2017
Please cite this article as: James E. Sharman, Tony Stanton, Christopher M. Reid, Anthony Keech, Philip Roberts-Thomson, Simon Stewart, Robert Greenough, Michael Stowasser, Walter P. Abhayaratna , Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study). The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Concli(2017), doi: 10.1016/ j.cct.2017.08.010
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
ACCEPTED MANUSCRIPT 1
Targeted LOWering of Central Blood Pressure in patients with hypertension: baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study) James E. Sharmana, Tony Stantonb,c, Christopher M. Reidd,e, Anthony Keechf, Philip RobertsThomsona,g, Simon Stewarth , Robert Greenoughi, Michael Stowasserj, Walter P. Abhayaratnai. a
PT
Menzies Institute for Medical Research, University of Tasmania, Hobart, AUSTRALIA. Sunshine Coast University Hospital, Birtinya, AUSTRALIA. cSchool of Medicine, University of Queensland, Brisbane, AUSTRALIA. dCentre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, AUSTRALIA. eSchool of Public Health, Curtin University, Perth, AUSTRALIA. fSydney Medical School, NHMRC Clinical Trials Centre, University of Sydney, Sydney, AUSTRALIA. gRoyal Hobart Hospital, Department of Cardiology, Hobart, AUSTRALIA h Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, AUSTRALIA. iAustralia National University, Canberra Hospital, Canberra, Australian Capital Territory, AUSTRALIA. jEndocrine Hypertension Research Centre, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, AUSTRALIA.
MA
NU
SC
RI
b
EP T
ED
Funding: The study is supported by a National Health and Medical Research Council of Australia (NHMRC) Project Grant (reference 103787). CMR and SS are supported by NHMRC Research Fellowships 1045862 and 1041796 respectively. Completion of this paper was made possible for JES through funding from the High Blood Pressure Research Council of Australia Franco-Australian Exchange Program, the Menzies Institute for Medical Research and a Mobility Scholarship from L’Institut Servier.
AC C
Corresponding author: Professor James E. Sharman Menzies Institute for Medical Research, University of Tasmania Private Bag 23, Hobart, 7000, AUSTRALIA. Phone: +61 3 6226 4709 Fax: +61 3 6226 7704 Email: [email protected] Running title: Targeted central blood pressure therapy
ACCEPTED MANUSCRIPT 2
Abstract Background. High blood pressure (BP) is the most common modifiable cause of death from cardiovascular disease. Lowering BP with medication improves patient outcomes, but even in populations with normal upper arm (brachial) BP there remains considerable residual risk for
PT
cardiovascular disease and this may be due to persistently elevated central BP. There has never been a trial to determine the value of targeted central BP lowering among patients with
RI
hypertension, and this was the aim of this study.
SC
Methods. This is a multi-centre, randomized, open-label, blinded endpoint trial among 308 patients treated for uncomplicated hypertension with controlled brachial BP (
